TickerFacts.

Halozyme Therapeutics, Inc. (HALO): Share Repurchases

Annual figures by period end, from SEC filings.

$342.37M
Year ended 2025-12-31
$371.61M
Trailing 12 months to 2026-06-30
+19.6%
3-year compound annual growth
+17.9%
5-year compound annual growth
$402.38M2017-12-31: $02018-12-31: $02019-12-31: $200.00M2020-12-31: $150.12M2021-12-31: $350.06M2022-12-31: $200.00M2023-12-31: $402.38M2024-12-31: $250.00M2025-12-31: $342.37M$342.37M
2017-12-31 Share Repurchases (USD) 2025-12-31
Period endedShare RepurchasesChange YoYSource filing
2025-12-31$342.37M+36.9%2026-02-17, From 2025-01-01
2024-12-31$250.00M-37.9%2026-02-17, From 2024-01-01
2023-12-31$402.38M+101.2%2026-02-17, From 2023-01-01
2022-12-31$200.00M-42.9%2025-02-18, From 2022-01-01
2021-12-31$350.06M+133.2%2024-02-20, From 2021-01-01
2020-12-31$150.12M-24.9%2023-02-21, From 2020-01-01
2019-12-31$200.00Mn/a2022-02-22, From 2019-01-01
2018-12-31$0n/a2021-02-23, From 2018-01-01
2017-12-31$0n/a2020-02-24, From 2017-01-01

Share Repurchases at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedShare RepurchasesChange YoY
Halozyme Therapeutics, Inc. (HALO)2025-12-31$342.37M+36.9%
Bio-Techne Corp (TECH)2026-06-30$41.67M-84.9%
Moderna, Inc. (MRNA)2025-12-31$2.00Mn/a
Qiagen N.V. (QGEN)2025-12-31$280.09M-4.1%
Exelixis, Inc. (EXEL)2026-01-02$947.51M+45.3%
Repligen Corp (RGEN)2025-12-31$0n/a
Neurocrine Biosciences Inc (NBIX)2025-12-31$167.70M-44.1%
ADMA Biologics, Inc. (ADMA)2025-12-31$31.94Mn/a
Biogen Inc. (BIIB)2024-12-31$0n/a

Compare HALO, TECH, MRNA, QGEN side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗